Summary
A study by the JDRF CGM study group published in Diabetes Care showed sustained benefits of CGM use on A1c, glucose profiles, and rates of hypoglycemia in intensively managed adult type 1 diabetes patients. Patients spent significantly more time with glucose levels in the range of 71-180 mg/dl (3.9-10 mmol/l) at 12 months and those with baseline A1c greater than 7% maintained an average drop in A1c of 0.4% ± 0.6%
Analysis
We see this data as very positive, though not completely surprising. We note especially the findings that patients using CGM had glucose levels within 71-180 mg/dl, given the extensive discussion of the negative impact of glycemic variability (both hyper- and hypo- glycemia) on long term outcomes. We think this bodes well for the broader adoption of CGM and think such data will push more and more doctors and patients to look seriously at adopting CGM.
Kelly Close consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
